Clinical Trial Update: IS-free Treg HaploHCT [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial at Dana-Farber Cancer Institute evaluating an IS-free regulatory T cell haploidentical hematopoietic cell transplantation to prevent gr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Graft-versus-host Disease
• Myelodysplastic Syndromes

Drugs mentioned

• IS-free regulatory T cell haploidentical hematopoietic cell transplantation

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Stem Cell Transplant Complications, Graft Vs Host Disease | Phase 1 | Status: RECRUITING